134069-68-4
| 中文名称 | 134069-68-4 |
|---|---|
| 中文同义词 | 化合物 T13107 |
| 英文名称 | TDN 345 |
| 英文同义词 | TDN 345;1-Oxa-3,8-diazaspiro[4.5]decan-2-one, 8-[4,4-bis(4-fluorophenyl)butyl]-3-(1,1-dimethylethyl)-4-methylene-;TDN345,TDN-345 |
| CAS号 | 134069-68-4 |
| 分子式 | C28H34F2N2O2 |
| 分子量 | 468.58 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 134069-68-4.mol |
| 结构式 |  |
134069-68-4 性质
| 沸点 | 556.2±60.0 °C(Predicted) |
|---|---|
| 密度 | 1.18±0.1 g/cm3(Predicted) |
| 储存条件 | Store at -20°C |
| 溶解度 | 溶于二甲基亚砜 |
| 酸度系数(pKa) | 9.67±0.20(Predicted) |
TDN345 A 是一种 Ca2+ 拮抗剂，主要用于血管和老年痴呆疾病，例如阿尔茨海默症的研究。
TDN-345 (10 μM) significantly increases the intracellular NGF content in the time-course study. TDN-345 induces NGF synthesis/secretion at the concentrations of 0.1 μM; statistically significant at 1 μM. The ED 50 is 0.88 μM.
TDN-345 (0.1-1.0 mg/kg, p.o.) dose-dependently decreases the mortality and ischemic neurological deficit score when administered orally twice, 60 min before ischemia and 90 min after recirculation. Additionally, TDN-345 (0.2 or 1.0 mg/kg, p.o. once daily for 3 weeks after the onset of stroke) decreases the mortality and recurrence of stroke in SHRSP.